...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024

toinv 


Great analysis of the presentation, it is an absolute travesty that this great science technology that Zenith and RVX have is being squandered by a pathetic management team led by DM who can't get anything done at any level , His best Move would be to pass the baton to Dr Lakohotia or someone else with Biotech management experience who is more respected than DM who can get a BP deal done at this point of the Zenith trials. I would love to hear DM is stepping aside at the Zenith AGM but i doubt that will happen with his big Ego 

Share
New Message
Please login to post a reply